Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BT17
UPID:
MTG1_HUMAN
Alternative names:
GTP-binding protein 7; Mitochondrial GTPase 1
Alternative UPACC:
Q9BT17; Q5VWX8; Q6PIY9; Q8IYJ4; Q8NC48; Q9BVU8
Background:
Mitochondrial ribosome-associated GTPase 1, also known as GTP-binding protein 7 or Mitochondrial GTPase 1, plays a crucial role in mitochondrial ribosome assembly and translational activity. Its GTPase activity is essential for mitochondrial function.
Therapeutic significance:
Understanding the role of Mitochondrial ribosome-associated GTPase 1 could open doors to potential therapeutic strategies.